Literature summary for 1.14.14.154 extracted from

Xu, B.; Wang, C.; Yang, J.; Mao, G.; Zhang, C.; Liu, D.; Tai, P.; Zhou, B.; Xia, G.; Zhang, M.
Silencing of mouse hepatic lanosterol 14-alpha demethylase down-regulated plasma low-density lipoprotein cholesterol levels by short-term treatment of siRNA (2008), Biol. Pharm. Bull., 31, 1182-1191.

Search for more literature for 1.14.14.154

Inhibitors

Inhibitors	Comment	Organism	Structure
siRNA	administrated single dose of 10 microg CYP51-siRNAs for 48 h results in significantly depletion of CYP51 mRNA in liver of mice fed on normal diet (from 40 to 60%). Exerts inhibition in a dose dependent manner (from 26% in 5 microg to 40% in 20 microg). Most inhibitive effect from day 3 to day 6 (over 50%) after treatment. Six days after administration of 30 microg CYP51-siRNAs (20 microg on day 0 and 10 microg on day 3), CYP51 mRNA and protein levels are significantly knocked down in mice liver. Low-density lipoprotein receptor expression is significantly elevated compared with controls in hepatic cells after CYP51-siRNAs. As a consequence, about 50% of sera low-density lipoprotein cholesterol are significantly reduced. Effect on low-density lipoprotein receptor increase and low-density lipoprotein cholesterol reduction lasts 8 days after a single 20 microg CYP51-siRNAs injection. CYP51-siRNAs can not cause any fatty liver compared with buffer-group and do not interfere with mice ovulation	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
liver	-	Mus musculus	-
lung	-	Mus musculus	-

Synonyms

Synonyms	Comment	Organism
CYP51	-	Mus musculus
lanosterol 14-alpha demethylase	-	Mus musculus

General Information

General Information	Comment	Organism
physiological function	cholesterol levels link-modulation system between cholesterol synthetic pathway through CYP51 and cholesterol transport pathway through low-density lipoprotein receptor in vivo	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)